Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Furiex Pharmaceuticals, Inc. | furx20121031_8k.htm |
Exhibit 99.1
Contact
Media/Analysts/Investors:
Sailash Patel
919.456.7814
sailash.patel@furiex.com
Furiex Reports Third Quarter 2012 Financial Results
Third Quarter 2012 Highlights:
|
● |
Milestone revenue of $10.0 million related to Priligy® regulatory milestones. |
|
● |
Royalty revenue of $5.6 million, an increase of $2.5 million (81.4%) from second quarter 2012. |
|
● |
Amended Loan and Security Agreement providing $30.0 million in additional funding. |
|
● |
Cash and short-term investments balance of $47.8 million as of September 30, 2012. |
MORRISVILLE, N.C. (November 1, 2012) - Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today reported its financial and operating results for the quarter ended September 30, 2012.
Furiex recorded third quarter milestone revenue of $10.0 million. These regulatory milestones were related to achievement of new country marketing approvals for Priligy® and became due from the Menarini Group upon closing of the new license agreement on July 30, 2012.
Furiex recorded third quarter royalty revenue of $5.6 million, compared to $1.3 million for the same period in the prior year and $3.1 million in the second quarter of 2012. Royalty revenue included royalties related to Nesina® and Liovel® sales in Japan, and Priligy® sales in various countries outside of the United States.
Research and development expenses were $14.8 million for the quarter ended September 30, 2012, compared to $12.0 million for the same period in the prior year. The increase in research and development expenses from the prior year quarter ended September 30, 2011 was a result of the decision to progress with MuDelta Phase III clinical trials in early 2012 and the costs associated with its continued development, partially offset by decreases in spending for the discontinued PPD-10558 program and completion of the Phase II clinical trial work related to MuDelta and JNJ-Q2.
Third quarter selling, general and administrative expenses were $3.2 million for 2012, compared to $2.1 million for the third quarter of 2011. The increase in selling, general and administrative expenses were due primarily to increases in non-cash stock compensation expense of $0.4 million and increases in consulting expenses of $0.4 million.
Interest expense of $0.8 million for the third quarter of 2012 related entirely to our loan agreement with MidCap Funding III, LLC and Silicon Valley Bank.
Net loss was $3.3 million for the third quarter of 2012, compared to $13.0 million for the third quarter of 2011. The decrease in net loss of $9.7 million during the third quarter of 2012, as compared to the third quarter of 2011, relates to the changes in revenue and expenses previously described.
Net loss per share for the third quarter of 2012 was $0.33, compared to $1.32 for the third quarter of 2011.
"The Furiex team continues to advance the MuDelta Phase III clinical trials," said June Almenoff, M.D., Ph.D., president and chief medical officer of Furiex. “We have recruited slightly more than 30% of our targeted patient enrollment needed to complete these pivotal studies.”
"We have made significant strides on multiple fronts,” added Fred Eshelman, Pharm.D., chairman of Furiex. “MuDelta development remains on track, Nesina and Liovel royalty revenue from Japan continues to ramp up, Takeda has resubmitted New Drug Applications for alogliptin and alogliptin/pioglitazone to the FDA, restructuring of the Priligy agreements is complete and immediately accretive, and we have secured $30 million in additional funding to support operations. We believe we have laid a sound foundation for the development of our product portfolio.”
Furiex will conduct a live conference call and webcast Friday, November 2, 2012, at 9:00 a.m. ET to discuss its third quarter 2012 results and financial outlook for 2012 as well as provide an overview of its business and pipeline. A Q&A session will follow. All interested parties can access the webcast through the Presentations & Events link in the Investors section of the Furiex website at www.furiex.com. The webcast will be archived shortly after the call for on-demand replay. The conference call will be broadcast live over the Internet and will also be available using the following direct dial numbers:
|
Participant dial-in: |
+1.877.677.9122 (U.S./Canada) |
|
+1.708.290.1401 (International) | |
|
Conference ID: |
35741137 |
About Furiex
Furiex Pharmaceuticals is a drug development collaboration company that uses innovative clinical development design to accelerate and increase value of drug development programs by advancing them through the drug discovery and development process in a cost-efficient manner. Our drug development programs are designed and driven by a core team with extensive drug development experience. The company collaborates with pharmaceutical and biotechnology companies and has a strong, diversified product portfolio and pipeline with multiple therapeutic candidates, including one Phase III-ready asset, two compounds in Phase III development, one of which is with a partner, and three products on the market. The company's mission is to develop innovative medicines faster and at a lower cost, thereby improving profitability and accelerating time to market while providing life-improving therapies for patients. For more information, visit www.furiex.com.
Except for historical information, all of the statements, expectations and assumptions contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although Furiex attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause actual results to differ materially include the following: continuing losses and our potential need for additional financing; the risk of finding collaborators for our late-stage product candidates; progress of product candidates in clinical trials and regulatory approvals as it relates to receiving future milestone payments; inability of our existing collaborators to effectively market approved products for which we receive royalty and sales-based milestone payments; the risks and expense of continuing the research and development activities of our existing candidates; changes in the safety and efficacy profile of our existing candidates as they progress through research and development; potential U.S. Food and Drug Administration changes to its regulatory guidance; new collaborative agreements that we might enter into in the future; the costs of defending or prosecuting any patent opposition or litigation necessary to protect our proprietary technologies; and the other risk factors set forth from time to time in the SEC filings for Furiex, copies of which can be found on our website.
FURIEX PHARMACEUTICALS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (In thousands, except per share data) Three Months Ended Nine Months Ended September 30, September 30, 2011 2012 2011 2012 Revenue: Milestones Royalties Total revenue Research and development expenses Selling, general and administrative expenses Depreciation and amortization Total operating expenses Operating loss Interest expense Other income, net Loss before provision for income taxes Provision for income taxes Net loss Net loss per basic and diluted share Weighted-average shares used to compute net loss per basic and diluted share:
$
—
$
10,000
$
—
$
20,000
1,272
5,577
2,505
11,297
1,272
15,577
2,505
31,297
12,024
14,798
38,123
54,919
2,100
3,209
6,424
8,732
19
22
64
64
14,143
18,029
44,611
63,715
(12,871
)
(2,452
)
(42,106
)
(32,418
)
136
837
136
1,386
—
—
—
—
(13,007
)
(3,289
)
(42,242
)
(33,804
)
6
(3
)
18
9
$
(13,013
)
$
(3,286
)
$
(42,260
)
$
(33,813
)
$
(1.32
)
$
(0.33
)
$
(4.28
)
$
(3.39
)
9,881
10,015
9,881
9,974
|
FURIEX PHARMACEUTICALS, INC. AND SUBSIDIARIES |
||||||||
|
CONSOLIDATED BALANCE SHEETS |
||||||||
|
(Unaudited) |
||||||||
|
(In thousands, except share data) |
||||||||
|
December 31, |
September 30, |
|||||||
|
2011 |
2012 |
|||||||
|
Assets |
||||||||
|
Current assets: |
||||||||
|
Cash and cash equivalents |
$ | 33,628 | $ | 40,342 | ||||
|
Short-term investments |
10,000 | 7,500 | ||||||
|
Accounts receivable, net |
1,985 | 7,519 | ||||||
|
Prepaid expenses |
214 | 589 | ||||||
|
Total current assets |
45,827 | 55,950 | ||||||
|
Property and equipment, net |
181 | 141 | ||||||
|
Goodwill |
49,116 | 49,116 | ||||||
|
Other assets |
— | 275 | ||||||
|
Total assets |
$ | 95,124 | $ | 105,482 | ||||
|
Liabilities and Shareholders’ Equity |
||||||||
|
Current liabilities: |
||||||||
|
Accounts payable |
$ | 147 | $ | 7,577 | ||||
|
Accrued expenses |
10,422 | 12,354 | ||||||
|
Current portion of long-term debt |
1,351 | 2,162 | ||||||
|
Total current liabilities |
11,920 | 22,093 | ||||||
|
Long-term debt, net |
8,649 | 37,838 | ||||||
|
Other long-term liabilities |
232 | 256 | ||||||
|
Total liabilities |
20,801 | 60,187 | ||||||
|
Common stock, $0.001 par value, 40,000,000 shares authorized; 9,949,422 and 10,015,297 shares issued and outstanding |
10 | 10 | ||||||
|
Preferred stock, $0.001 par value, 10,000,000 shares authorized; no shares issued or outstanding |
— | — | ||||||
|
Paid-in capital |
158,438 | 163,223 | ||||||
|
Accumulated deficit |
(84,125 | ) | (117,938 | ) | ||||
|
Total shareholders’ equity |
74,323 | 45,295 | ||||||
|
Total liabilities and shareholders’ equity |
$ | 95,124 | $ | 105,482 | ||||